Shares of Spark Therapeutics Inc (NASDAQ:ONCE) ended Thursday session in red amid volatile trading. The shares closed down -6.45 points or -13.74% at $40.51 with 2.51 million shares getting traded. Post opening the session at $46.50, the shares hit an intraday low of $35.07 and an intraday high of $46.50 and the price vacillated in this range throughout the day. The company has a market cap of $1.24 billion and the numbers of outstanding shares have been calculated to be 30.62 million shares.
Spark Therapeutics Inc (ONCE) and Pfizer Inc. (PFE) declared recently that Lindsey A. George, M.D., a hematologist and attending physician at the Children’s Hospital of Philadelphia and lead investigator in the Phase 1/2 clinical trial of SPK-9001 for treatment of hemophilia B, will present an updated dataset from the ongoing Phase 1/2 clinical trial of SPK-9001 at the 58th American Society of Hematology (ASH) Annual Meeting, to be held Dec. 3-6, 2016, in San Diego. The conference abstract, counting a plot of factor IX activity levels (as a % of normal) expressed over time by the first seven participants as of Aug. 4, 2016, was made available recently:
The results are from the first seven participants who received a single administration of investigational SPK-9001 at a dose of 5 x 1011 vector genomes (vg)/kg body weight. Four of the seven participants had reached greater than 12 weeks post-vector administration at the time of abstract submission; those four participants practiced consistent and sustained factor IX activity levels, with a mean greater than 30% of normal, with no sustained elevation in liver enzyme levels.
Shares of QLT Inc. (USA) (NASDAQ:QLTI) ended Thursday session in red amid volatile trading. The shares closed down -0.03 points or -1.83% at $1.61 with 16,022 shares getting traded. Post opening the session at $1.63, the shares hit an intraday low of $1.59 and an intraday high of $1.67 and the price vacillated in this range throughout the day. The company has a market cap of $84.71 million and the numbers of outstanding shares have been calculated to be 52.83 million shares.
QLT Inc. (USA) (QLTI) stated financial results recently for the third quarter ended September 30, 2016.
During the third quarter of 2016, research and development (“R&D”) expenditures were $2.9 million contrast to $2.1 million for the same period in 2015. The $0.8 million (38%) increase was mainly because of higher costs related to preparatory activities for our forthcoming Phase III pivotal trial for QLT091001.
The operating loss for the third quarter of 2016 was $6.0 million, contrast to $2.8 million for the same period in 2015. The net $3.2 million change in our operating loss was mainly because of a $2.7 million non-recurring termination fee received from InSite in September 2015, in connection with InSite’s termination of the merger agreement, in addition to higher R&D costs in the third quarter of 2016 associated with preparatory activities for our forthcoming Phase III pivotal trial for QLT091001.